David A. Siegel Novo Cure LTD Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Novo Cure LTD stock. As of the latest transaction made, Two Sigma Advisers, LP holds 189,500 shares of NVCR stock, worth $2.15 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
189,500
Previous 441,400
57.07%
Holding current value
$2.15 Million
Previous $7.87 Million
57.11%
% of portfolio
0.01%
Previous 0.02%
Shares
31 transactions
Others Institutions Holding NVCR
# of Institutions
276Shares Held
75.7MCall Options Held
920KPut Options Held
130K-
Black Rock Inc. New York, NY12.1MShares$138 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$122 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.9MShares$78.3 Million9.53% of portfolio
-
Capital World Investors Los Angeles, CA6.38MShares$72.4 Million0.02% of portfolio
-
State Street Corp Boston, MA2.68MShares$30.4 Million0.0% of portfolio
About NovoCure Ltd
- Ticker NVCR
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 104,950,000
- Market Cap $1.19B
- Description
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...